MCID: INS001
MIFTS: 61

Insulinoma malady

Categories: Rare diseases, Gastrointestinal diseases, Endocrine diseases, Cancer diseases

Aliases & Classifications for Insulinoma

About this section
Sources:
11Disease Ontology, 13DISEASES, 27GTR, 31ICD10 via Orphanet, 35LifeMap Discovery®, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 50Novoseek, 54Orphanet, 62SNOMED-CT, 68UMLS, 69UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Insulinoma:

Name: Insulinoma 35 11 48 54 27 50 39 13 68
Islet Cell Adenoma 11 68
Experimental Organism Islet Cell Adenoma Neoplasm 68
 
Insulin-Producing Tumor of Islet Cells 11
Adenoma Islet Cell 50
Islet Cell Tumor 68

Characteristics:

Orphanet epidemiological data:

54
insulinoma:
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Ireland),1-9/1000000 (Worldwide),1-9/1000000 (Japan); Age of onset: All ages

Classifications:



External Ids:

Disease Ontology11 DOID:3892
Orphanet54 ORPHA97279
MESH via Orphanet40 D007340
UMLS via Orphanet69 C0021670
ICD10 via Orphanet31 E16.8

Summaries for Insulinoma

About this section
NIH Rare Diseases:48 Insulinoma is a type of pancreatic neuroendocrine tumor (pancreatic net), which refers to a group of rare tumors that form in the hormone-making cells of the pancreas. insulinomas, specifically, produce too much insulin, a hormone that reduces the level of sugar in the blood by helping it move into cells. as a result, people with insulinomas generally have very low blood sugar levels which can be associated with anxiety, confusion, hunger, a fast heart rate, and sweating. in severe cases, it can lead to seizures, coma or even death. ninty percent of insulinomas are benign (noncancerous). in most cases, the underlying cause of insulinoma is unknown. however, people with specific genetic syndromes such as multiple endocrine neoplasia type i, von hippel-lindau syndrome, neurofibromatosis type 1, and tuberous sclerosis are at risk of insulinomas and other endocrine tumors. treatment generally includes surgery to remove the tumor. last updated: 4/26/2016

MalaCards based summary: Insulinoma, also known as islet cell adenoma, is related to metastatic insulinoma and adult-onset non-insulinoma persistent hyperinsulinemic hypoglycemia, and has symptoms including Array, Array and Array. An important gene associated with Insulinoma is INSM1 (INSM Transcriptional Repressor 1), and among its related pathways are Cori Cycle and Hepatic ABC Transporters. Affiliated tissues include the pancreas, pancreas and heart, and related mouse phenotypes are growth/size/body region and endocrine/exocrine gland.

Disease Ontology:11 An adenoma that is located in the pancreas and is characterized by overproduction of insulin.

Wikipedia:71 An insulinoma is a tumor of the pancreas that is derived from beta cells and secretes insulin. It is a... more...

Related Diseases for Insulinoma

About this section

Diseases related to Insulinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 133)
idRelated DiseaseScoreTop Affiliating Genes
1metastatic insulinoma11.9
2adult-onset non-insulinoma persistent hyperinsulinemic hypoglycemia11.8
3pancreatitis10.5
4hypoglycemia10.4
5retinal melanoma10.3INSM1, PTPRN
6posterior myocardial infarction10.2INSM1, PTPRN
7paranasal sinus cancer, adult10.2INS, MEN1, SST
8pemphigus foliaceus10.2MEN1, SST
9paroxysmal nonkinesigenic dyskinesia 210.2INS, PTPRN
10urethra clear cell adenocarcinoma10.2INS, MEN1, SST
11multiple endocrine neoplasia10.2
12tabes dorsalis10.2MEN1, SCT, SST
13secondary syphilis10.2CHGA, SST
14microphthalmia, syndromic 810.2GCG, INS
15thrombophilia10.2INS, MEN1, SST
16retinal vascular occlusion10.2INS, SCT, SST
17brain edema10.2CHGA, SST
18uterine ligament cancer10.1MEN1, SST
19hepatitis10.1
20fibrosis of extraocular muscles, congenital, 3c10.1PDX1, SCT
21choline deficiency disease10.1INS, SST
22spinal stenosis10.1CHGA, INS, SST
23antidepressant type abuse10.1GCK, INS, PTPRN
24mitochondrial complex ii deficiency10.1CHGA, MEN1, SST
25cowden syndrome 310.1CHGA, MEN1, SST
26cardioauditory syndrome of sanchez cascos10.1CHGA, MEN1, SST
27gmppa-cdg10.1CHGA, SCT, SST
28hepatitis b reinfection following liver transplantation10.1CHGA, MEN1, SST
29parathyroid carcinoma10.1CHGA, MEN1, SCT
30adult ependymoblastoma10.1CHGA, MEN1
31diaphanospondylodysostosis10.0ABCC8, GCK
32shaken baby syndrome10.0INS, SST
33neutropenia, severe congenital, 5, autosomal recessive10.0CHGA, MEN1, SST
34nosophobia10.0ABCC8, GCK
35glucagonoma10.0
36keloids10.0CHGA, INS, MEN1, SST
37vestibular gland benign neoplasm10.0CHGA, INS, MEN1, SST
38labyrinthine unilateral reactive loss10.0ABCC8, GCK, INS
39endocrine gland cancer10.0CHGA, MEN1, SST
40progressive relapsing multiple sclerosis10.0CHGA, MEN1, SCT, SST
41leukemia, acute promyelocytic, somatic10.0CHGA, MEN1, SCT, SST
42peripheral degeneration of cornea10.0GCG, INS, SCT, SST
43obesity10.0
44gastrinoma10.0
45alopecia-mental retardation syndrome 29.9ABCC8, INS, SLC2A2
46gemistocytic astrocytoma9.9GCG, MEN1, SCT, SST
47blind loop syndrome9.9GCG, GCK, INS
48epilepsy9.9
49duodenitis9.9
50acute pyelonephritis9.9CHGA, INS, MEN1, SCT, SST

Graphical network of the top 20 diseases related to Insulinoma:



Diseases related to insulinoma

Symptoms & Phenotypes for Insulinoma

About this section

Human phenotypes related to Insulinoma:

 54 64 (show all 35)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hearing abnormality64 54 Occasional (29-5%) HP:0000364
2 abnormality of vision64 54 Occasional (29-5%) HP:0000504
3 behavioral abnormality54 Frequent (79-30%)
4 anxiety64 54 Occasional (29-5%) HP:0000739
5 hyperinsulinemic hypoglycemia64 54 Very frequent (99-80%) HP:0000825
6 hyperinsulinemia54 Very frequent (99-80%)
7 hyperhidrosis64 54 Very frequent (99-80%) HP:0000975
8 seizures64 54 Very frequent (99-80%) HP:0001250
9 lethargy64 54 Occasional (29-5%) HP:0001254
10 coma64 54 Occasional (29-5%) HP:0001259
11 tremor64 54 Very frequent (99-80%) HP:0001337
12 nonketotic hypoglycemia64 54 Very frequent (99-80%) HP:0001958
13 palpitations64 54 Very frequent (99-80%) HP:0001962
14 recurrent hypoglycemia64 54 Very frequent (99-80%) HP:0001988
15 zollinger-ellison syndrome64 54 Frequent (79-30%) HP:0002044
16 abnormal rapid eye movement (rem) sleep54 Occasional (29-5%)
17 polyphagia64 54 Frequent (79-30%) HP:0002591
18 generalized muscle weakness64 54 Frequent (79-30%) HP:0003324
19 paresthesia64 54 Occasional (29-5%) HP:0003401
20 increased body weight64 54 Frequent (79-30%) HP:0004324
21 reduced consciousness/confusion54 Frequent (79-30%)
22 abnormality of the pancreatic islet cells64 54 Very frequent (99-80%) HP:0006476
23 pituitary prolactin cell adenoma64 54 Frequent (79-30%) HP:0006767
24 fluctuations in consciousness64 54 Frequent (79-30%) HP:0007159
25 primary hyperparathyroidism64 54 Frequent (79-30%) HP:0008200
26 fasting hyperinsulinemia64 54 Very frequent (99-80%) HP:0008283
27 transient global amnesia64 54 Very frequent (99-80%) HP:0010534
28 abnormality of pain sensation64 54 Occasional (29-5%) HP:0010832
29 abnormality of higher mental function54 Occasional (29-5%)
30 reactive hypoglycemia64 54 Frequent (79-30%) HP:0012051
31 fatigue64 54 Occasional (29-5%) HP:0012378
32 neoplasm of the adrenal gland64 54 Occasional (29-5%) HP:0100631
33 neuroendocrine neoplasm64 54 Occasional (29-5%) HP:0100634
34 insomnia64 54 Occasional (29-5%) HP:0100785
35 abnormal rapid eye movement sleep64 HP:0002494

MGI Mouse Phenotypes related to Insulinoma according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053788.1CHGA, GCK, GLP1R, IAPP, INS, INSM1
2MP:00053797.5ABCC8, CHGA, GCK, GLP1R, INS, INSM1
3MP:00053765.4ABCC8, CHGA, GCK, GLP1R, IAPP, INS

Drugs & Therapeutics for Insulinoma

About this section

Drugs for Insulinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 128)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1Liver ExtractsPhase 4, Phase 3, Phase 2, Phase 14067
2pancreatic polypeptidePhase 4, Phase 2, Phase 3, Phase 120
3
FluorouracilapprovedPhase 2, Phase 3185651-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
4
LevoleucovorinapprovedPhase 2, Phase 3, Phase 172868538-85-2
Synonyms:
(6S)-5-Formyl-5,6,7,8-tetrahydrofolic acid
(6S)-5-formyltetrahydrofolic acid
(6S)-Folinic acid
(6S)-Leucovorin
 
(S)-Leucovorin
Citrovorum factor
L-Folinic acid
Levofolene
Levofolinic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid
5
Bevacizumabapproved, investigationalPhase 2, Phase 32020216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
6
Exenatideapproved, investigationalPhase 2, Phase 3, Phase 1, Early Phase 1296141758-74-915991534
Synonyms:
141732-76-5
141758-74-9
286014-72-0
335149-21-8
AC 2993
AC 2993 LAR
AC 2993A
AC-2993
AC002993
AC2993
AC2993a
Bydureon
Byetta
 
C074031
CHEBI:490990
CHEMBL414357
Ex4 peptide
Exenatide
Exenatide Synthetic
Exenatide synthetic
Exendin 4
Exendin 4 (Heloderma suspectum)
Exendin-4
Extendin-4
LY2148568
Synthetic exendin-4
UNII-9P1872D4OL
7
Oxaliplatinapproved, investigationalPhase 2, Phase 3, Phase 1146061825-94-35310940, 9887054, 6857599, 9887054, 43805
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
Oxalatoplatin
 
Oxalatoplatinum
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
Oxaliplatino [Spanish]
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
oxaliplatin
oxaliplatine
oxaliplatino
oxaliplatinum
8
Fentanylapproved, illicit, investigational, vet_approvedPhase 3821437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
1-phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl CII
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
 
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
UNII-UF599785JZ
fentanyl
9
Folic Acidapproved, nutraceutical, vet_approvedPhase 2, Phase 3439259-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
Folsaeure
 
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
10
leucovorinapproved, NutraceuticalPhase 2, Phase 3, Phase 1323558-05-954575, 6560146, 143
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R,S)-5-Formyltetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formyltetrahydrofolic acid
Acide folinique
Calcium citrovorum factor
Calcium folinate
Citrovorum factor
Folinate
Folinic acid
Folinic acid calcium salt
 
Folinic acid calcium salt USP27
Folinic acid-SF
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
L-Leucovorin
L-N-[p-[[(2-Amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-Glutamic acid
L-leucovorin
Leucal
Leucovorin calcium
Leucovorin folinic acid
Leucovorinum
Leukovorin
Levoleucovorin
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyl-THF
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
Welcovorin
Wellcovorin
folinate
11Hormone AntagonistsPhase 3, Phase 2, Phase 1, Early Phase 113180
12Angiogenesis Modulating AgentsPhase 2, Phase 3, Phase 14185
13HormonesPhase 3, Phase 2, Phase 1, Early Phase 114415
14Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 3, Phase 2, Phase 1, Early Phase 113168
15Angiogenesis InhibitorsPhase 2, Phase 3, Phase 14257
16Immunosuppressive AgentsPhase 2, Phase 3, Phase 113086
17AntimetabolitesPhase 2, Phase 3, Phase 112054
18IncretinsPhase 2, Phase 3, Phase 1, Early Phase 11579
19Antimetabolites, AntineoplasticPhase 2, Phase 3, Phase 17361
20Hypoglycemic AgentsPhase 2, Phase 3, Phase 1, Early Phase 15896
21Anesthetics, IntravenousPhase 32538
22Central Nervous System DepressantsPhase 313403
23Peripheral Nervous System AgentsPhase 323689
24Anesthetics, GeneralPhase 32934
25NarcoticsPhase 33646
26Cinacalcet HydrochloridePhase 371
27Calcium, DietaryPhase 3, Phase 2, Phase 15713
28AnestheticsPhase 39596
29Adjuvants, AnesthesiaPhase 31674
30Calcimimetic AgentsPhase 371
31Analgesics, OpioidPhase 33238
32AnalgesicsPhase 311733
33FolateNutraceuticalPhase 2, Phase 34392
34Vitamin B9NutraceuticalPhase 2, Phase 34392
35ColaNutraceuticalPhase 3, Phase 2, Phase 11946
36
Gefitinibapproved, investigationalPhase 2361184475-35-2123631
Synonyms:
184475-35-2
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
4-(3'-chloro-4'-Fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
AC-1556
AC1L3X0A
AKOS000280752
BCB03_000781
Bio-0046
C419708
CCRIS 9011
CHEBI:49668
CHEMBL939
CID123631
CU-00000000396-1
D01977
DB00317
DB07998
EC-000.2409
EN002708
FT-0081035
Gefitini
Gefitinib
Gefitinib (JAN/USAN/INN)
Gefitinib [USAN]
Gefitinib, Iressa, ZD1839
Gelfitinib
HMS2089B19
I01-1227
 
IRE
Iressa
Iressa (TN)
Iressa(TM)
Irressat
K00240
KBioSS_002241
Kinome_3321
Kinome_3322
LS-139916
MolPort-000-883-335
N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
N-(3-chloro-4-Fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine
NCGC00159455-02
NCGC00159455-03
NSC715055
S1025_Selleck
STK621310
UNII-S65743JHBS
ZD 1839
ZD-1839
ZD-1839, Iressa, Gefitinib
ZD1839
ZINC19632614
gefitinib
nchembio.117-comp18
nchembio866-comp14
37
Octreotideapproved, investigationalPhase 2, Phase 122383150-76-9383414, 6400441
Synonyms:
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
79517-01-4 (acetate salt)
83150-76-9
AC1L1GVU
AC1L8LCD
AC1L9M4X
C07306
C5H12O2.C4H10
CHEBI:427278
CHEBI:611465
CHEMBL1680
CID383414
CID448601
CID54374
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide
D00442
DRG-0115
HMS2090C09
HS-2020
 
L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*
L000453
LS-177735
LS-187135
Longastatin
NCGC00181796-01
NCI60_025753
Octreotida
Octreotida [Spanish]
Octreotide
Octreotide (USAN/INN)
Octreotide Acetate Salt
Octreotide [USAN:INN:BAN]
Octreotide-LAR
Octreotidum
Octreotidum [Latin]
Octrotide
SAN 201-995
SM 201-995
SMS 201-995
SMS-201-995
Sandostatine
Sandoz 201-995
UNII-RWM8CCW8GP
nchembio.184-comp3
zacycloicosane-4-carboxamide acetate
38
MelphalanapprovedPhase 2729148-82-34053, 460612
Synonyms:
(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid
(2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid
148-82-3
3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3025 C.B.
3025 c.b
3223-07-2
4-(Bis(2-chloroethyl)amino)-L-phenylalanine
4-14-00-01689 (Beilstein Handbook Reference)
4-[Bis(2-chloroethyl)amino]-L-phenylalanine
4-[Bis-(2-chloroethyl)amino]-L-phenylalanine
AC1LA2OE
ALKERAN (TN)
AY3360000
Alanine Nitrogen Mustard
Alkeran
AmbotzHAA1563
At-290
BIDD:GT0044
BRD-K87827419-001-02-8
BRN 2816456
BSPBio_002407
C13H18Cl2N2O2
CB 3025
CB-3025
CCRIS 374
CHEBI:165415
CHEBI:28876
CHEMBL852
CID460612
D00369
DivK1c_000653
EINECS 205-726-3
HMS2090B09
HMS2091B16
HMS502A15
HSDB 3234
IDI1_000653
KBio1_000653
KBio2_000877
KBio2_003445
KBio2_006013
KBio3_001627
KBioGR_001284
KBioSS_000877
L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine
L-PAM
L-Phenylalanine mustard
L-Sarcolysin
L-Sarcolysine
L-Sarkolysin
LS-15868
LS-865
 
Levofalan
Levofolan
Levopholan
M2011_SIGMA
MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN))
MLS001333666
MLS002153368
Melfalan
Melfalano
Melfalano [INN-Spanish]
Melphalan (JP15/USP/INN)
Melphalan [USAN:INN:BAN:JAN]
Melphalanum
Melphalanum [INN-Latin]
Mephalan
MolPort-003-665-535
NCGC00090757-01
NCGC00090757-02
NCGC00090757-03
NCI-C04853
NINDS_000653
NIOSH/AY3360000
NSC 241286
NSC 8806
NSC-8806
NSC241286
NSC8806
P-Di-(2-chloroethyl)amino-L-phenylalanine
P-L-Sarcolysin
P-N-Bis(2-chloroethyl)amino-L-phenylalanine
Phenylalanine mustard
Phenylalanine nitrogen mustard
Prestwick_1006
RCRA waste no. U150
Rcra waste number U150
SK-15673
SMP2_000174
SMR000058720
SPBio_000287
SPECTRUM1500382
Sarcolysine
Sarkolysin
Spectrum2_000074
Spectrum3_000684
Spectrum4_000882
Spectrum5_001601
Spectrum_000397
TL8001065
TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN)
TRANSGENIC MODEL EVALUATION (MELPHALAN)
UNII-Q41OR9510P
melphalan
p-Bis(beta-chloroethyl)aminophenylalanine
p-Di-(2-chloroethyl)amino-L-phenylalanine
p-L-Sarcolysin
p-L-sarcolysine
p-N,N-bis(2-chloroethyl)amino-L-phenylalanine
p-N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-Di(chloroethyl)aminophenylalanine
p-N-di(chloroethyl)aminophenylala nine
phenylalanine nitrogen mu stard
39
Miconazoleapproved, investigational, vet_approvedPhase 2, Phase 1370622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
40
Sirolimusapproved, investigationalPhase 2, Phase 1194053123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
41
Sorafenibapproved, investigationalPhase 2700284461-73-0216239, 406563
Synonyms:
284461-73-0
4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide
4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE
AB1004622
AC-1674
AC1L50CF
BAX
BAY 43-9006
BAY 43-9006 (free base)
BAY 43-9006 tosylate salt
BAY 439006
BAY 54-9085 (tosylate salt)
BAY-43-0006
BAY-43-9006
BAY-54-9085
BAY43-9006
BRD-K23984367-001-01-8
Bio-0100
CHEBI:47228
CHEBI:50924
CHEMBL1336
CID216239
 
D08524
DB00398
DB07438
EN002709
I06-0856
K00597a
Kinome_766
LS-186067
LS-187021
LS-187788
MolPort-003-850-270
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea
N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
NCGC00167488-01
NSC-724772
NSC747971
Nexavar
STK627350
Sorafenib
Sorafenib (INN)
Sorafenib [INN]
Sorafenib tosylate
Sorafenibum
UNII-9ZOQ3TZI87
ZINC01493878
nchembio.117-comp17
sorafenib
sorafenibum
42
Irinotecanapproved, investigationalPhase 2112397682-44-5, 100286-90-660838
Synonyms:
(+)-Irinotecan
(4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE
(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate
1u65
97682-44-5
AC-7469
AC1L1U0Z
AC1Q6PGI
BRD-K08547377-003-02-4
BSPBio_002346
Bio-0054
Biotecan
Biotecan (TN)
C16641
C33H38N4O6
CHEBI:105985
CHEMBL481
CID60838
CP0
Campothecin-11
Campto
Camptosar
 
Camptosar, Campto, CPT-11, Irinotecan
Camptothecin-11
D08086
DB00762
FT-0083650
HSDB 7607
IRINOTECAN HYDROCHLORIDE Trihydrate
IRINOTECAN, CPT-11
Irinotecan (INN)
Irinotecan Hcl
Irinotecan Hydrochloride
Irinotecan Hydrochloride Trihydrate
Irinotecan [INN:BAN]
Irinotecan hydrochloride
Irinotecanum
Irinotecanum [INN-Latin]
LS-44589
NCI60_005051
NSC728073
S1198_Selleck
TL8006026
UNII-7673326042
irinotecan
43
EverolimusapprovedPhase 2, Phase 11940159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
44
PancrelipaseapprovedPhase 2, Phase 197053608-75-6
Synonyms:
1,4-alpha-D- glucan glucanohydrolase
PA
 
Pancreatic alpha-amylase precursor
Pancrelipase (amylase
lipase
protease)
45
Capecitabineapproved, investigationalPhase 2, Phase 11342154361-50-960953
Synonyms:
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
AC1L1U83
AC1Q4KU8
Ambap154361-50-9
C110904
C12650
C15H22FN3O6
CAPE
CAPECITABINE
CHEBI:31348
CHEMBL1773
CID60953
Capecitabin
Capecitabina
Capecitabine (JAN/USAN/INN)
Capecitabine [USAN]
Capecitabinum
Capecitibine
Capiibine
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
Caxeta
 
D01223
DB01101
FT-0082472
HSDB 7656
LS-59070
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
R-340
R340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978/000
S1156_Selleck
UNII-6804DJ8Z9U
Xabine
Xeloda
Xeloda (TN)
Xeloda, Captabin, Capecitabine
ZINC03806413
capecitabina
capecitabine
capecitabinum
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
46
CisplatinapprovedPhase 2277015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
47
StreptozocinapprovedPhase 2918883-66-429327
Synonyms:
-nitrosomethylharnstoff
1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea
18883-66-4
2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose
2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose
2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose
2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose
AB00513906
AC1L1H7V
Ambap18883-66-4
BCBcMAP01_000142
BPBio1_000754
BSPBio_000684
BSPBio_002734
C07313
CHEBI:9288
CHEMBL1603
CID29327
D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)- (9CI)
D05932
DB00428
DivK1c_000531
Estreptozocina
HMS1921A07
HMS2092I09
HMS501K13
IDI1_000531
KBio1_000531
KBio2_001440
KBio2_004008
KBio2_006576
KBio3_001954
KBioGR_001768
KBioSS_001440
MolPort-003-665-493
N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine
N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff
 
N-D-Glucosyl-(2)-N'-nitrosomethylurea
N-D-Glucosyl-(2)-n'
N-D-Glucosyl-(2)-n'-nitrosomethylurea
NCGC00178500-01
NCGC00178500-02
NINDS_000531
Prestwick3_000732
S0130_SIAL
S0130_SIGMA
S1312_Selleck
SMP1_000282
SPBio_000243
SPECTRUM1500543
STREPTOZOTOCIN
STRZ
Spectrum2_000062
Spectrum3_001087
Spectrum4_001244
Spectrum5_001047
Spectrum_000960
Streptozocin
Streptozocin (USAN/INN)
Streptozocin, Zanosar, STZ,Streptozotocin
Streptozocine
Streptozocine [INN-French]
Streptozocinium
Streptozocinium [Latin]
Streptozocinum
Streptozocinum [INN-Latin]
Streptozotocin
UNII-5W494URQ81
ZINC03977737
Zanosar
Zanosar (TN)
alkylating agent
binds to DNA
streptozocin
streptozosin
48
SomatostatinapprovedPhase 2, Phase 123738916-34-6, 51110-01-153481605
Synonyms:
growth hormone-inhibiting hormone (GHIH)
 
somatotropin release-inhibiting factor (SRIF)
somatotropin release-inhibiting hormone
49
Bortezomibapproved, investigationalPhase 2807179324-69-7387447, 93860
Synonyms:
179324-69-7
AC1L8TUW
Bortezomib
Bortezomib (JAN/USAN/INN)
CHEBI:287372
CHEBI:41143
CHEMBL325041
CID387447
D03150
DB07475
DPBA
FT-0082488
I14-3268
LDP-341
LDP341
LPD 341
LPD-341
 
MLN341
MolPort-003-845-298
N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE
N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
NCI60_029010
NSC-681239
NSC681239
PROSCRIPT BORONIC ACID
PS-341
Pyz-Phe-boroLeu
S1013_Selleck
SBB071337
Velcade
Velcade (TN)
Velcade, MG-341, PS-341, Bortezomib
[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
[(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
bortezomib
50
Temozolomideapproved, investigationalPhase 2, Phase 171185622-93-15394
Synonyms:
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide
3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-1,2,3,5-tetrazine-8-carboxamide
3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-as-tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-D)(1,2,3,5)tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide
3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
8-Carbamoyl-3-methylimidazo(5,1-D)-1,2,3,5-tetrazin-4(3H)-one
8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
85622-93-1
AC-758
AC1L1K9B
BIDD:GT0204
BRN 5547136
Bio-0147
C047246
C6H6N6O2
CCRG 81045
CCRG-81045
CCRIS 8996
CHEBI:153686
CHEMBL810
CID5394
CPD000466338
D06067
DB00853
Essex brand of temozolomide
HMS2051O12
HMS2090B08
I06-0149
I14-1943
LS-80558
M B 39831
M & B 39831
M&B 39831
M&B-39831
 
M-39831
MB 39831
MLS000759447
MLS001424028
MLS002701861
Methazolastone
NCGC00167429-01
NCGC00167429-02
NCI60_003316
NSC 362856
NSC-362856
NSC362856
SAM001246636
SMR000466338
STK623541
Sch 52365
Sch-52365
Schering brand of temozolomide
Schering-Plough brand of temozolomide
TL8005593
TMZ
TMZ-Bioshuttle
Temodal
Temodal (TN)
Temodar
Temozolamide
Temozolodida
Temozolodida [Spanish]
Temozolomid
Temozolomida
Temozolomide (JAN/USAN/INN)
Temozolomide [INN:BAN]
Temozolomidum
Temozolomidum [Latin]
Témozolomide
UNII-YF1K15M17Y
ZINC01482184
m & b 39831
temozolomide

Interventional clinical trials:

(show all 48)
idNameStatusNCT IDPhase
1Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine TumorsUnknown statusNCT00454376Phase 4
2Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine TumorsUnknown statusNCT00227617Phase 2, Phase 3
3Cinacalcet to Treat Familial Primary HyperparathyroidismCompletedNCT00325104Phase 3
4Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
5New Imaging Procedure for the Localisation of Insulinoma and Transplanted Islet CellsRecruitingNCT02127541Phase 2, Phase 3
6Effect of Gelofusine on GLP1-receptor ImagingCompletedNCT02541734Phase 1, Phase 2
7Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine TumorsCompletedNCT00131911Phase 2
8Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine TumorsCompletedNCT00075439Phase 2
9Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine CancerCompletedNCT00454363Phase 2
10PS-341 in Treating Patients With Metastatic Neuroendocrine TumorsCompletedNCT00017199Phase 2
11Thalidomide in Treating Patients With Metastatic Neuroendocrine TumorsCompletedNCT00027638Phase 2
12Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By SurgeryCompletedNCT00416767Phase 2
13AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine TumorsCompletedNCT00427349Phase 2
14Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine TumorsCompletedNCT00602082Phase 2
15Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver CancerCompletedNCT00096083Phase 2
16Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine TumorsRecruitingNCT02259725Phase 2
17Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell CancerActive, not recruitingNCT01010126Phase 2
18Trial of Intranasal Insulin in Children and Young Adults at Risk of Type 1 DiabetesActive, not recruitingNCT00336674Phase 2
19Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine TumorsActive, not recruitingNCT01824875Phase 2
20Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine TumorsActive, not recruitingNCT01525082Phase 2
21Reversing Type 1 Diabetes After it is EstablishedActive, not recruitingNCT01106157Phase 1, Phase 2
22Pasireotide in Hyperinsulinemic HypoglycemiaNot yet recruitingNCT03053284Phase 2
23Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With SurgeryTerminatedNCT02031536Phase 2
24Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine TumorsTerminatedNCT00084461Phase 2
25Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney CancerTerminatedNCT02273752Phase 2
26Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine TherapyTerminatedNCT01056601Phase 2
27Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine TumorsTerminatedNCT00466856Phase 2
28Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine TumorsWithdrawnNCT02108782Phase 2
29Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine TumorsWithdrawnNCT00227773Phase 2
30Whole Body 111In-exendin-4 Imaging Study in Insulinoma PatientsCompletedNCT00937079Phase 1
31Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
32Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine CarcinomaCompletedNCT01204476Phase 1
33Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid TumorsCompletedNCT00049023Phase 1
34Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent CancerCompletedNCT00006368Phase 1
35Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the PeritoneumCompletedNCT00005860Phase 1
36Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic CancerCompletedNCT00005842Phase 1
37Laser Tissue Welding - Distal Pancreatectomy Sealing StudyRecruitingNCT03147768Phase 1
38Everolimus and Vatalanib in Treating Patients With Advanced Solid TumorsActive, not recruitingNCT00655655Phase 1
39Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine TumorNot yet recruitingNCT02831179Phase 1
40Indium In 111 Pentetreotide in Treating Patients With Refractory CancerTerminatedNCT00002947Phase 1
4168Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of NesidioblastosisUnknown statusNCT02560376Early Phase 1
42Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine TumorsUnknown statusNCT00730483
43Laparoscopy to Remove Pancreatic Tumors (Insulinomas)CompletedNCT00005910
44Diagnosing and Treating Low Blood Sugar LevelsRecruitingNCT00001276
45EUS-guided Ethanol Ablation of an InsulinomaActive, not recruitingNCT02121366
4618F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic HypoglycemiaAvailableNCT01916148
4718F-FDOPA PET in Neuroendocrine TumoursAvailableNCT02431715
48Gastroenteral-Pancreatic Neuroendocrine Tumors in TaiwanEnrolling by invitationNCT02102893

Search NIH Clinical Center for Insulinoma


Cochrane evidence based reviews: insulinoma

Genetic Tests for Insulinoma

About this section

Genetic tests related to Insulinoma:

id Genetic test Affiliating Genes
1 Insulinoma27

Anatomical Context for Insulinoma

About this section

MalaCards organs/tissues related to Insulinoma:

36
Pancreas, Heart, Testes, Pancreatic islet, Liver, Eye, Pituitary

FMA organs/tissues related to Insulinoma:

17
The pancreas

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Insulinoma:
id TissueAnatomical CompartmentCell Relevance
1 PancreasIslets of LangerhansMature Beta Cells Affected by disease

Publications for Insulinoma

About this section

Articles related to Insulinoma:

(show top 50)    (show all 897)
idTitleAuthorsYear
1
A new marker, insulinoma-associated protein 1 (INSM1), for high-grade neuroendocrine carcinoma of the uterine cervix: Analysis of 37 cases. (27908529)
2017
2
Diagnostic Performance of 48-Hour Fasting Test and Insulin Surrogates in Patients With Suspected Insulinoma. (28230660)
2017
3
Quantitative proteomic profiling of the extracellular matrix of pancreatic islets during the angiogenic switch and insulinoma progression. (28071719)
2017
4
A Clinicopathological Study of Malignant Insulinoma in a Contemporary Series. (27984486)
2017
5
Insulinoma Detection With MDCT: Is There a Role for Whole-Pancreas Perfusion? (27929662)
2017
6
Endoscopic ultrasound-guided ethanol ablation therapy for pancreatic insulinoma: an unusual strategy. (28458908)
2017
7
Baicalein protects rat insulinoma INS-1 cells from palmitate-induced lipotoxicity by inducing HO-1. (28445528)
2017
8
Characteristics of glucose metabolism indexes and continuous glucose monitoring system (CGMS) in patients with insulinoma. (28293303)
2017
9
Endoscopic Ultrasound-Guided Ethanol Ablation for Control of Local-Regional Metastatic Insulinoma. (28187109)
2017
10
Geniposide improves insulin production and reduces apoptosis in high glucose-induced glucotoxic insulinoma cells. (28363490)
2017
11
Insulinoma - The incremental value of somatostatin receptor positron emission tomography. (28217530)
2017
12
T372R Mutation Status in Yin Yang 1 Gene in Insulinoma Patients. (28472826)
2017
13
Case of insulinoma manifesting as hyperinsulinemia after discontinuing quetiapine in an elderly patient with delirium. (28508501)
2017
14
Decreased levels of Fibroblast Growth Factor 21 are correlated with improved hypoglycemia in patients with insulinoma. (28225059)
2017
15
Hypoglycemia identified by a continuous glucose monitoring system in a second-trimester pregnant woman with insulinoma: a case report. (28427440)
2017
16
Paroxysmal Hypertension Induced by an Insulinoma. (28202863)
2017
17
Seizures Due to Insulinoma- A Rare but Treatable Cause. (28462560)
2017
18
Prospective comparison of biphasic contrast-enhanced CT, volume perfusion CT, and 3 Tesla MRI with diffusion-weighted imaging for insulinoma detection. (28419614)
2017
19
Small pancreatic insulinoma: Successful endoscopic ultrasound-guided radiofrequency ablation in a single session using a 22-G fine needle. (28295664)
2017
20
Sporadic Insulinoma as a Rare Cause of Recurrent Hypoglycemia in Children. (28512591)
2017
21
Postprandial hypoglycemia as the only manifestation of insulinoma: exceptional case report. (28416239)
2017
22
Development of (111)In-labeled exendin(9-39) derivatives for single-photon emission computed tomography imaging of insulinoma. (28089587)
2017
23
Novel prokaryotic expression of thioredoxin-fused insulinoma associated protein tyrosine phosphatase 2 (IA-2), its characterization and immunodiagnostic application. (27881117)
2016
24
Microcystin-LR induces dysfunction of insulin secretion in rat insulinoma (INS-1) cells: Implications for diabetes mellitus. (27107231)
2016
25
Concomitant Insulinoma and Type 2 Diabetes Mellitus Diagnoses: A Case Report. (27075402)
2016
26
Insulinoma After Bariatric Surgery: Diagnostic Dilemma and Therapeutic Approaches. (26846121)
2016
27
Non-insulinoma Pancreatogeneous Hypoglycemia Syndrome with False-Positive Somatostatin Receptor Scintigraphy: A Case Report and Review of Literature. (27276748)
2016
28
Liver Metastases 10 Years after Resection of a "Benign" Insulinoma. (28206926)
2016
29
Glycemic control in patients with insulinoma. (28222404)
2016
30
Expression of the insulinoma-associated 1 (insm1) gene in Xenopus laevis tadpole retina and brain. (27670931)
2016
31
Giant insulinoma in a 15-year-old man: A case report. (27258815)
2016
32
Recurrent Seizures Due to Pancreatic Insulinoma. (27739279)
2016
33
Diagnosis of insulinoma using the ratios of serum concentrations of insulin and C-peptide to glucose during a 5-hour oral glucose tolerance test. (27725372)
2016
34
Insulinoma due to multiple pancreatic microadenoma localized by multimodal imaging. (27504852)
2016
35
The imidazoline compound RX871024 promotes insulinoma cell death independent of AMP-activated protein kinase inhibition. (27221730)
2016
36
The role of endosomal cholesterol trafficking protein, StAR-related lipid transfer domain 3 (StarD3/MLN64), in BRIN-BD11 insulinoma cells. (27679500)
2016
37
Giant Malignant Insulinoma. (26969167)
2016
38
A Case of 36-Year-Old Woman With Recurrent Hypoglycemia Due to Insulinoma With Cytokeratin-19 Expression: A Marker of Poor Prognosis. (26752258)
2016
39
Focal hepatic glycogenosis associated with metastatic insulinoma presenting as mass lesions. (26627264)
2016
40
Insulinoma or non-insulinoma pancreatogenous hypoglycemia? A diagnostic dilemma. (27887024)
2016
41
P-selectin-mediated LOX expression promotes insulinoma growth in Rip1-Tag2 mice by increasing tissue stiffness. (27877081)
2016
42
Multiple Endocrine Neoplasia Type 1 Presenting as Hypoglycemia due to Insulinoma. (27247513)
2016
43
DPP-4 (CD26) inhibitor sitagliptin exerts anti-inflammatory effects on rat insulinoma (RINm) cells via suppressing NF-I_B activation. (27612849)
2016
44
Erratum to: Uptake of a fluorescent L-glucose derivative 2-NBDLG into three-dimensionally accumulating insulinoma cells in a phloretin-sensitive manner. (26886928)
2016
45
Giant insulinoma: report of a case and review of published reports. (27864816)
2016
46
Insulinoma Causing Prolonged Hypoglycaemic Coma. (27656487)
2016
47
Operation for insulinomas in multiple endocrine neoplasia type 1: When pancreatoduodenectomy is appropriate. (27863775)
2016
48
Tumor-specific promoter-driven adenoviral therapy for insulinoma. (26902080)
2016
49
Diagnostic Difficulties in a Pediatric Insulinoma: A Case Report. (26986124)
2016
50
Tumor Heterogeneity Detected by 68Ga DOTATOC and 18F-FDG PET/CTs in One Malignant Insulinoma With Involvement of the Portal Splenic Confluence and Ovarian Metastases. (27607168)
2016

Variations for Insulinoma

About this section

Expression for genes affiliated with Insulinoma

About this section
Search GEO for disease gene expression data for Insulinoma.

Pathways for genes affiliated with Insulinoma

About this section

Pathways related to Insulinoma according to GeneCards Suite gene sharing:

(show all 11)
idSuper pathwaysScoreTop Affiliating Genes
19.9INS, SLC2A2
2
Show member pathways
9.2GCK, INS, PDX1, SLC2A2
38.9GCG, GCK, SLC2A2
48.8GCG, INS, PDX1, WFS1
5
Show member pathways
8.8GCK, IAPP, INS, INSM1, PDX1, SLC2A2
6
Show member pathways
8.8GCG, GLP1R, IAPP, SCT
78.8GCG, GLP1R, IAPP, SCT
8
Show member pathways
8.7ABCC8, GCK, INS, PDX1, SLC2A2
98.7ABCC8, GCK, INS, PDX1, SLC2A2
10
Show member pathways
8.3ABCC8, GCG, GLP1R, INS, SLC2A2
11
Show member pathways
7.6ABCC8, GCG, GCK, GLP1R, INS, PDX1

GO Terms for genes affiliated with Insulinoma

About this section

Cellular components related to Insulinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1secretory granuleGO:00301419.3CHGA, PTPRN, PTPRN2
2endoplasmic reticulum lumenGO:00057889.0GCG, INS, MEN1, PTPRN2, WFS1
3transport vesicle membraneGO:00306588.8CHGA, PTPRN, PTPRN2

Biological processes related to Insulinoma according to GeneCards Suite gene sharing:

(show all 16)
idNameGO IDScoreTop Affiliating Genes
1detection of glucoseGO:005159410.4GCK, PDX1
2negative regulation of gluconeogenesisGO:004572110.4GCK, INS
3negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayGO:190223610.4PDX1, WFS1
4negative regulation of type B pancreatic cell apoptotic processGO:200067510.4PDX1, WFS1
5positive regulation of glycogen biosynthetic processGO:004572510.4GCK, INS
6cellular glucose homeostasisGO:000167810.3ABCC8, GCK
7negative regulation of vasodilationGO:004590810.2CHGA, INS
8transdifferentiationGO:006029010.2INSM1, PDX1
9cellular protein metabolic processGO:004426710.2IAPP, INS, MEN1, WFS1
10glucose metabolic processGO:000600610.2GCK, INS, PDX1
11regulation of potassium ion transportGO:004326610.1GCK, KCNA5
12glucose transportGO:001575810.1GCK, INS, SLC2A2
13insulin secretion involved in cellular response to glucose stimulusGO:00357739.9PTPRN, PTPRN2
14glucose homeostasisGO:00425939.9GCK, INS, PDX1, WFS1
15type B pancreatic cell differentiationGO:00033099.8INSM1, MEN1, PDX1
16regulation of insulin secretionGO:00507968.3ABCC8, GCG, GCK, GLP1R, KCNA5, SLC2A2

Molecular functions related to Insulinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1hormone activityGO:00051798.6GCG, IAPP, INS, SCT, SST

Sources for Insulinoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet